The headline safety figures — and what they actually mean

Across more than 19,000 treated cases logged since ChondroFiller entered clinical use in 2013, post-market surveillance data have recorded zero serious adverse device effects (SADEs) — defined as unintended consequences causing organ damage, hospitalisation, or lasting injury. The overall device complaint rate sits at approximately 0.06%, and the most frequently logged device issue is non-gelation (the scaffold failing to polymerise correctly inside the defect), occurring in roughly 0.01% of cases. When it does occur, non-gelation is classified as a procedural outcome rather than a patient-harm event.

Those figures come from Meidrix Biomedicals GmbH's Clinical Evaluation Report, Version 09, published in April 2025. Two things are worth knowing about that document. First, a Clinical Evaluation Report is not an optional white paper: it is a mandatory regulatory submission required under EU Medical Device Regulation for every CE Class III device — the highest-risk device tier — which gives it a defined legal and evidential character. Second, the data it consolidates are manufacturer-sponsored rather than drawn from an independent patient registry, and that provenance should be held in mind when reading the headline numbers.

What the dataset does provide is unusually large-scale real-world surveillance — spanning more than a decade of clinical use across more than 20 European countries — with a complaint rate described by independent commentators as among the lowest recorded in the cartilage-repair field. Independent peer-reviewed corroboration exists, including a 2025 prospective study by Matta et al. (PMC12498443) that found no significant complication difference between ChondroFiller-treated patients and controls in wrist cartilage repair, though that study cannot substitute for a large independent registry. Taken together, the evidence paints a consistent picture — one that this article unpacks in the sections that follow.

Expected reactions in the first 48–72 hours

The three most common sensations in the first 48–72 hours after a ChondroFiller injection — localised joint swelling, a temporary pain flare, and stiffness — are expected physiological responses to the scaffold material, not signs of a complication.

Swelling typically peaks around 24 hours as the joint responds to the newly placed collagen scaffold. A dull ache may accompany this, along with some restriction in the joint's range of motion. Both usually resolve spontaneously within two to three days without any medical intervention.

Knowing the difference between an expected response and an adverse event is useful here: an expected response reflects the body registering a biological material and beginning the integration process — the healing mechanism working as intended, rather than something going wrong. These early sensations fall clearly into the expected category; they appear consistently across the treated population and were not classified as adverse events in post-market surveillance.

During this initial window, protecting the joint from unnecessary loading is advisable. The scaffold requires time to set and integrate with the surrounding tissue, and early mechanical stress may interfere with that process.

Rare risks and who should not have ChondroFiller

Several categories of patient are not suitable for ChondroFiller, and for some the exclusion is absolute.

The most important is known hypersensitivity to collagen or rat-derived proteins. ChondroFiller uses murine-derived Type I collagen — effective as a scaffold material, but a potential allergen for patients with that specific sensitivity. No allergic reaction was recorded across the 19,000-plus case dataset, making the risk extremely uncommon in practice; it remains an absolute contraindication because the biological mechanism is real and the consequences of an intra-articular allergic response would be serious.

Further absolute contraindications include active joint infection, a bleeding disorder, active malignancy, and advanced osteoarthritis classified as Kellgren-Lawrence Grade IV. That last criterion is worth underlining: the device's safety record applies to focal cartilage defects in joints with otherwise intact surrounding cartilage, not to end-stage or diffuse joint disease. Patients with KL Grade IV osteoarthritis require a different clinical pathway, and neither the procedure nor its favourable safety profile should be generalised to that group.

Defect scale also matters. The supporting evidence — including Simeonov et al.'s 2024 case series in the Journal of IMAB, which endorses ChondroFiller specifically for younger patients with lesions under 2 cm² — relates to well-defined focal defects, not large or confluent cartilage loss. The established indication covers defects up to 6 cm².

Finally, the six-week period of protected weight-bearing that follows the procedure is a biomechanically necessary clinical requirement, not optional recovery guidance. The scaffold must integrate with surrounding tissue before full load-bearing can safely resume, and that timeline is a prerequisite patients need to understand and commit to before proceeding.

How the complication rate compares to surgical alternatives

Putting a complication rate in perspective requires a reference point, and the CER provides one by drawing on independent surgical literature for comparison.

The CER places ChondroFiller's complication rate at approximately 0% and its reoperation rate at roughly 3–8%. Against that, the same document cites complication rates of 0–7% for microfracture and up to 17% for ACI/MACI procedures, with reoperation rates reaching up to 41% for microfracture and up to 37% for ACI/MACI. The direction of the comparison is consistent, and the gap is substantial.

One caveat is worth stating plainly. The ChondroFiller figures come from the same manufacturer-sponsored CER discussed throughout this article, while the surgical benchmarks draw on independent registry and trial literature. This is not a controlled head-to-head study. The comparison is directionally informative — it situates ChondroFiller within a wider landscape — but it should not be read as the equivalent of a randomised trial placing one treatment directly against another.

It is also worth noting that microfracture and ACI/MACI are surgical procedures involving theatre admission, general or regional anaesthesia, and a distinct post-operative recovery pathway. They are also indicated for partially overlapping but not identical patient groups. ChondroFiller, by contrast, is placed under ultrasound guidance in an outpatient setting. The treatments sit in different parts of the cartilage-repair pathway, and the lower procedural burden of the injection route is part of why patients and clinicians may consider it where the indication fits.

Which patients the safety record applies to

Regulatory certification and access conditions carry practical weight for UK patients considering ChondroFiller. The device holds CE Class III status — the highest risk tier under EU medical device regulation — and is available through appropriately qualified clinicians across more than 20 European countries. That certification obliges the manufacturer to compile and submit continuous post-market safety evidence, which is the formal mechanism by which the CER and its 19,000-case dataset exist.

In the UK, ChondroFiller is not routinely funded by the NHS and is not covered by most major private insurers, so patients typically access it through self-funded private appointments. The treatment is delivered as an ultrasound-guided outpatient injection; there is no theatre admission or general anaesthetic in the current delivery model.

The safety figures reviewed throughout this article reflect outcomes in appropriately selected patients — those meeting the clinical criteria for focal cartilage defects in otherwise healthy joints. Whether those criteria apply to any individual depends on imaging findings, defect characteristics, and wider medical history that no article can evaluate. A specialist clinical review, drawing on joint imaging and a full clinical history, is the appropriate mechanism for determining personal suitability.

The state of the evidence and where it still needs to grow

Independent peer review of ChondroFiller's safety, while growing, remains limited in scale. Matta et al.'s 2025 prospective study (PMC12498443) found no significant difference in complication rates between ChondroFiller-treated patients and controls in wrist cartilage repair — meaningful corroboration, though drawn from a single joint site. Simeonov et al. (Journal of IMAB, 2024) adds a second peer-reviewed voice, supporting its use in focal defects smaller than 2 cm² in younger patients. No large independent registry equivalent to the manufacturer's CER exists yet, and that is the most substantive gap in the current evidence picture.

European structural repair data — MOCART scores of 81.6 to 84.3 across published studies (MOCART is a standardised MRI scoring system for cartilage repair quality, where higher scores indicate better defect fill and tissue integration) — provide useful context on scaffold behaviour, but these figures come from European study populations rather than UK-specific cohorts. Long-term follow-up beyond the CER's current horizon is a further area where the evidence base is still developing.

None of this undermines the existing safety signal. Twelve years of post-market surveillance across a large and diverse treated population have produced a consistent picture — but it is a picture drawn primarily from a single manufacturer-compiled dataset. The honest verdict at this stage is reassuring, not settled, and a comparable independent registry would considerably strengthen the foundation.